Biologics to watch in 2013
02.01.2013 - At the beginning of the new year, 29 monoclonal antibody (mAbs) drugs are in Phase III clinical development.
While around 350 therapeutic mAbs are currently in clinical development globally, only 28 had entered active Phase 2/3 or Phase 3 studies as of January 2013, according to MABS. Additionally one mAb mixture was under evaluation in Phase III. Historically, mAbs that target antigens relevant to cancer have comprised approximately 50% of the mAb clinical pipeline, but in 2013 the picture has changed: 66% or 19 of the antibodies to watch in 2013 are for non-cancer indications.
The non-cancer mAbs include alirocumab (Regeneron; Sanofi, hypercholesterinemia); AMG 145 (Amgen, hypercholesterinemia), epratuzumab (UCB, SLE), gantenerumab (Roche; Alzheimer’s disease), gevokizumab (Xoma/Servier, Non-infectious uveitis), itolizumab (Biocon, Plaque psoriasis), ixekizumab (Eli Lilly and Co., psoriasis), lebrikizumab (Roche/Genentech, rheumatoid arthritis), mepolizumab (GSK, Asthma, COPD etc.), ocrelizumab (Roche/Genentech, multiple sclerosis), reslizumab (Teva, Eosinophilic asthma), romosozumab (Amgen, Postmenopausal osteoporosis), sarilumab (Regeneron; Sanofi, rheumatoid arthritis), secukinumab (Novartis, rheuma, psoriasis), sirukumab (Janssen R&D LLC, rheumatoid arthritis), solanezumab (Eli Lilly and Co., Alzheimer’s disease), tabalumab (Eli Lilly and Co., rheuma, SLE) and vedolizumab (Millenium, Ulcerative colitis; Crohn disease). The mixture of actoxumab and bezlotoxumab (MK-3415A, Merck & Co.) is being evaluated in two Phase 3 studies as a treatment for Clostridium difficile infection.
The ten cancer mAbs are: elotuzumab (Bristol-Myers Squibb, Abbott, multiple myeloma), farletuzumab (Morphotek, ovarian cancer), inotuzumab ozogamicin (Pfizer; UCB, ALL, NHL), naptumomab estafenatox (Active Biotech, renal cell carcinoma), necitumumab (ImClone LLC, NSCL), nivolumab (Bristol-Myers Squibb, NSCL, renal cell carcinoma), obinutuzumab (Roche/Genetech, Diffuse large B cell lymphoma, CLL, NHL), onartuzumab (Roche/Genetech, NSCL cancer; gastric cancer), racotumomab (CIMAB; Laboratorio Elea S.A.C.I.F. y A, NSCL), and ramucirumab (ImClone LLC, Gastric; liver, breast, colorectal, NSCL cancers).